◀ Back to MMP7
FASLG — MMP7
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Yamamoto et al., Drug design and discovery 1999
:
Recently, we have reported that
FasL is processed to a soluble form by an unknown metalloproteinase at the cell surface and some hydroxamate
matrix metalloproteinase ( MMP ) inhibitors
inhibit the processing similar to the case observed with TNF-1alpha
Mitsiades et al., Cancer Res 2001
(Colonic Neoplasms...) :
Matrix metalloproteinase-7 mediated cleavage of
Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity ...
MMP-7 efficiently cleaved recombinant FasL in vitro and
reduced cell surface
FasL expression
Tsukinoki et al., Clin Exp Nephrol 2004
(Disease Progression...) :
The results suggest that : ( 1 ) upregulation of mesangial FasL may contribute to the glomerular inflammation in proliferative lupus nephritis in vivo ; ( 2 ) proinflammatory cytokines, in particular IL1beta, produced in nephritis can upregulate FasL via the transcription factor NFkappaB in HMC ; and ( 3 )
MMP-7 mediated release of soluble
FasL could control the mesangial inflammation
Meng et al., Gynecol Oncol 2004
(MAP Kinase Signaling System...) :
Flow cytometry showed that LPA strongly upregulated FasL expression on the OVCAR3 cell surface ( P < 0.01 ), yet in Dov13 cells, LPA significantly upregulated
FasL expression only in the
presence of the general
matrix metalloproteinase ( MMP ) inhibitors GM6001 and MMP inhibitor II ( P < 0.01 )
Zhou et al., Scientific reports 2013
:
Tubule-specific knockout of ß-catenin diminished renal induction of matrix metalloproteinase (
MMP-7 ), which
induced FasL expression in interstitial fibroblasts and potentiated fibroblast apoptosis in vitro